Osteosarcoma is the most common bone tumor in children and young adults, with few advances in survival and treatment, especially for metastatic disease, in the last 30 years. Recently, immunotherapy has begun to show promise in various adult cancers, but the utility of this approach for osteosarcoma remains relatively unexplored. In this review, we outline the mechanisms and status of immunotherapies currently in clinical trials as well as future therapies on the horizon, and discuss their potential application for osteosarcoma.
INTRODUCTION
Osteosarcoma is the most common cancer originating in the bone, and typically affects adolescents and young adults. Although the primary tumor is often surgically resected, patients remain at high risk for eventually developing pulmonary metastases unless adjuvant chemotherapy is administered. Even then, only two-thirds of patients with initially localized disease are expected to be cured, with long-term survival occurring in <30% of patients with metastatic or recurrent tumors. 1 The inability to effectively optimize existing treatments or identify new active agents has prevented any improvement in outcome for over three decades. Given these limitations, novel treatment approaches are needed.
Several lines of evidence suggest that osteosarcoma may be susceptible to immune-based therapies. Osteosarcoma tumors have a higher percentage of CD8 + infiltrating lymphocytes than other sarcoma subtypes, 2 and the degree of infiltration correlates positively with survival. 3 Osteosarcomas have a high level of genomic instability, with some tumors expressing the programmed cell death protein-1 ligand (PD-L1), 4 suggesting potential sensitivity to inhibitors of the programmed cell death protein-1 (PD-1)/PD-L1 axis. [5] [6] [7] In addition, there are multiple cell surface proteins that are potentially targetable with antibodies. But perhaps the most compelling data Abbreviations: APC, antigen presenting cells; BiTE, bispecific T-cell engager; CAR-T, chimeric antigen receptor T cells; CTLA-4, cytotoxic T-lymphocyte associated protein-4; CTLs, cytotoxic T lymphocytes; DC, dendritic cells; NK cell, natural killer cell; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; Tgf-, transforming growth factor-beta; TILs, tumor-infiltrating lymphocytes; Tregs, T-regulatory cells
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. come from past experience with mifamurtide, which is an analog of bacterial cell walls that can trigger the activation of monocytes and macrophages and improve tumor control. Mifamurtide is currently approved in Europe for the treatment of osteosarcoma, based in part on a randomized phase III study showing improved overall survival in patients with osteosarcoma receiving mifamurtide plus conventional chemotherapy. 8 In this review, we outline the mechanisms and current status of immunotherapies that are now in clinical trials, as well as those on the horizon for the treatment of osteosarcoma (Figure 1 ).
Cancer immunotherapy
The immune system is a highly sophisticated organization of cells that work together to provide protection against foreign threats (e.g. infection, tumor) while maintaining tolerance against self. The interplay between the patient's immune system and cancer is complex and includes immune surveillance, immune cell infiltration, and tumor cytolysis by the host, which are counteracted by tumor defenses that dampen the immune response through the release of inhibitory cytokines and downregulation of surface markers. 9 A popular model that captures this interplay is termed cancer "immunoediting," which consists of the following three different phases: elimination, F I G U R E 1 Immune-based therapies for osteosarcoma. Green arrows represent stimulation. Red stops represent suppression. NK cell, natural killer cell; Treg, T-regulatory cell; CTLA-4, cytotoxic T-lymphocyte associated protein-4; TIM-3, T cell immunoglobulin and mucin domain-containing-3; LAG-3, lymphocyte activation gene 3 protein; IL-2, interleukin-2; TNF-, tissue necrosis factor alpha; MHC, major histocompatibility complex; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; CAR-T, chimeric antigen receptor T cell; BiTE, bispecific T-cell engager antibody equilibrium, and escape. 10 Elimination involves the identification of cancer-specific neoantigens, formation of tumor-reactive T-cells, and subsequent destruction of tumor cells. Unfortunately, some cancer cells have the ability to survive the elimination phase and enter the equilibrium stage, in which tumor growth is held dormant by the adaptive immune system, which may provide long-lasting and highlyspecific responses against cancer cells. However, some cells may ultimately evolve and evade the immune system, leading to the escape phase with subsequent proliferation and T-cell exhaustion. 10, 11 The mechanisms behind the tumor cell evasion include loss of tumor antigen expression, downregulation of human leukocyte antigens (HLA) from cancer cell surfaces, and recruitment of T-regulatory cells (Tregs), myeloid derived suppressor cells, or tumor-associated M2 macrophages, which all increase immunosuppression. These changes may lead to the upregulation of inhibitory receptors (e.g., cytotoxic T-lymphocyte associated protein-4 [CTLA-4], PD-1) on T cells, or of inhibitory ligands (e.g., PD-L1) on tumor cells. [12] [13] [14] Immunotherapies aim to counteract this escape phase and reinvigorate the patient's immune system to recognize and destroy cancerous cells.
Antibody targeting of cell surface proteins

Mechanism
The use of antibodies to target cancer cell surface proteins is attractive given the multiple antigens that are potentially targetable in osteosarcoma, the safety and ready availability of these "off-the-shelf" treat- Despite these early disappointments, further studies are ongoing with antibodies against other cell surface proteins such as disialoganglioside (GD2), which is widely expressed in both primary and recurrent osteosarcoma tumors. 21 As shown in Table 1 (CTLs). 24 Matured autologous DC can be loaded with the particle(s) of choice, treated with immunoadjuvants ex vivo, and then re-injected into the patient.
Experience in osteosarcoma and future directions
DC vaccines have produced delays in disease progression and even the regression of established osteosarcomas in animal models. 25 However, only limited activity was seen in the two clinical trials using DC vaccines pulsed with autologous tumor cell lysate in patients with recurrent osteosarcoma. 26, 27 These studies did, however, show that this strategy is safe and can activate the immune system to some extent.
It is unknown whether vaccines would be more effective for osteosarcoma in a setting of minimal residual disease, or whether combination with other immunotherapies would improve tumor control. In an effort to increase efficacy, investigators are adding decitabine to upregulate cancer antigen expression (NCT01241162), or gemcitabine to increase the tumor cell cytotoxicity and decrease myeloid-derived suppressor cells (NCT01803152).
TA B L E 1 Clinical trials for antibody therapy targeting cell surface proteins
Trial identifier Eligible disease(s) Treatments
Oncolytic viruses 1.4.1 Mechanism
Oncolytic viruses are attenuated viruses genetically engineered to only replicate in malignant cells. This strategy is appealing for solid tumor therapy because these viruses are not dependent on the expression of specific tumor cell antigens. In addition to direct cytotoxicity, the administration of oncolytic virus creates a pro-inflammatory tumor microenvironment leading to antigen presentation and APC maturation with subsequent epitope spreading. 28
Experience in osteosarcoma and future directions
Preclinical studies using various different oncolytic virotherapies have demonstrated activity against some adult cancers. In the clinic, talimogene laherparepvec (T-VEC) was found to produce responses in patients with melanoma even in noninjected metastatic tumors, and the success of this strategy has led to T-VEC being the first FDAapproved oncolytic virus. 29 A trial combining T-VEC with the anti-PD-1
antibody pembrolizumab is now being tested in patients with sarcoma (NCT03069378), and oncolytic viruses specifically for osteosarcoma are in preclinical development. 30-32
1.5 Adoptive cell therapy
Mechanism
Adoptive cell therapy provides a patient with cytolytic cells to cause an antitumor response. 23 35 There are currently two ongoing trials with GD2-targeted CAR-T cells (NCT 01953900 and NCT02107963).
There are also encouraging preclinical data showing the benefit of NK cells in animal models of osteosarcoma, [44] [45] [46] and several NK trials are ongoing (Table 2) Finally, investigators have explored the use of T cells, which may bridge the innate and adoptive responses, and which have an affinity to recognize and lyse osteosarcoma cells. 45 Preclinical studies demonstrated that T-cell treatment of mouse models of osteosarcoma had dramatic tumor regression. 46 Further in vitro and in vivo studies demonstrated significant enhancement of tumor killing when zoledronic acid was combined with the T cells against osteosarcoma tumors, leading to a potential combination therapy for patients with osteosarcoma, 45, 47 although not yet clinically validated.
Checkpoint inhibitors 1.6.1 Mechanism
Without ex vivo expansion, endogenous TILs often fail to control tumors because malignant cells escape immune surveillance by dampening the immune response via checkpoint ligands. 48 Checkpoint inhibitors reverse this process by reinvigorating the T-cell-mediated antitumor responses against tumor antigens through the major histocompatibility complex, 16 with the greatest response directed at neoantigens that are distinct from those on host tissues. 49 The complex genome and chromosomal instability seen in osteosarcoma tumors has not been proven to lead a high mutational burden; however, high levels of genetic instability have the potential to generate neo-epitopes that are the substrate for immune-mediated killing, thus making this tumor attractive for therapy with checkpoint inhibitors, including those targeting CTLA-4, PD-1, and PD-L1. 5, 7, 50 CTLA-4 is a transmembrane glycoprotein receptor expressed on
Tregs and memory T cells, and after binding to CD80/86 on DC results in functional inhibition. 51 CLTA-4 expression is increased in patients with osteosarcoma compared to healthy subjects, leading to the proposed use of CTLA-4 inhibitors in patients with osteosarcoma. 52, 53 PD-1 is another transmembrane immunoglobulin family member expressed on T cells, with the highest expression seen in chronically activated T cells. 54 PD-1 serves as a "brake" of the immune system by suppressing CTLs and activating Treg cells, 55 and its ligand PD-L1 is expressed on a subset of osteosarcoma tumor cells as well as immune cells contained within osteosarcoma tumor samples. 56 The success of checkpoint inhibitors for several different adult cancers has driven considerable interest in their potential application for osteosarcoma treatment.
Experience in osteosarcoma and future directions
Merchant et al. reported a pediatric phase I study of the CTLA-4
inhibitor ipilimumab in children with relapsed solid tumors, including eight with osteosarcoma. 57 They showed similar toxicity and pharmacokinetics as adults, with an increase in activated and cycling
CTLs without an increase in Tregs. Unfortunately, no objective antitumor responses were observed. The Sarcoma Alliance for
Research through Collaboration consortium recently tested pembrolizumab for the treatment of sarcomas, and reported partial response in one (4%) of the 22 patients with recurrent osteosarcoma. 58 Numerous studies are now testing various combinations of CTLA-4, PD-1, and PD-L1 inhibition, as discussed below and listed in Table 3 .
Combination therapies
The complexity of the immune system coupled with the disappointing activity seen with the single-therapy approaches studied to date suggest that combination strategies will be necessary to optimize 
BIOMARKERS
A major challenge for immunotherapy is the identification of biomarkers that predict response, so that treatments can be tailored for the greatest benefit. For checkpoint inhibitors, various proposed predictors of response include the tumor immune phenotype (expression of PD-1 and PD-L1, as well as the presence of TILs), the somatic genomic features such as mutational burden and microsatellite instability, the gut microbiome, 77 and the HLA class I genotype. 78 Unfortunately, PD-L1 expression has not been consistently predictive of response in either melanoma or NSCLC. 79, 80 Adding further complexity, PD-L1 expression is heterogeneous in both primary and metastatic lesions. 59, 81 Whether higher levels of TILs are predictive of response to PD-1-targeted therapy is being assessed but is as yet unknown. 67 Tumor mutational burden is another potential biomarker for PD-1 therapies, given the greater number of neoantigens. Specifically, tumors with mismatch repair deficiency (MMRD) have a striking response rate to pembrolizumab. 82 However, this biomarker is subject to other influences such as chemotherapy and radiation, and outside of MMRD does not always suffice as a stand-alone predictor. In the end, it is most likely to be a composite of biomarkers that will be utilized together to be predictive.
For treatments based on a specific antigenic target, that target must be widely expressed on tumor cells but not on host cells for optimum benefit. 83 However, even widespread target expression does not guarantee activity. 20, 21 Reliable predictive factors for other immunotherapies remain elusive at present.
Targeting immunosuppression in the microenvironment
There are numerous factors causing immunosuppression within the tumor microenvironment, and some of these can potentially be targeted for therapy. Transforming growth factor-beta (TGF-) is a growth factor present in the tumor microenvironment of osteosarcoma that stimulates tumor growth. 84 The expression of TGF-is higher in patients with osteosarcoma than that in healthy individuals, higher in metastatic disease versus localized disease, and correlates with a lack of response to chemotherapy. 85 Preclinical osteosarcoma murine models showed antitumor effects when TGF-blockade was combined with DC, due to immune response reconstitution. 86 A second approach uses the tyrosine kinase inhibitor axitinib, a vascular endothelial growth factor inhibitor and platelet-derived growth factor receptor inhibitor, to facilitate T-cell trafficking into the tumor microenvironment, and a trial of this agent combined with pembrolizumab is currently underway (NCT02636725). Other strategies explored in adults include combining PD-1 agents with specific inhibitors of IDO, 87 given the known immunosuppressive properties of IDO including the arrest of T-cell proliferation and induction of Tregs. 88 This combination strategy may be attractive for osteosarcoma, given the ubiquitous expression of IDO reported in primary osteosarcoma tumors. 89 
TA B L E 3 Clinical trials of checkpoint inhibitor therapy
CONCLUSION
Progress toward improving outcomes in patients with osteosarcoma has been limited in the last three decades by the failure to identify either new active agents or ways to optimize the use of existing drugs, not unlike many adult solid tumors before the advent of immunotherapies. Several biological features of osteosarcoma suggest that modulation of the immune response could lead to benefits, and the wide variety of therapeutic approaches now available make this an exciting time for immunotherapy. However, the sheer complexity of the immune system and the nuances of the tumor-specific microenvironment underscore how daunting this task is. As seen with conventional chemotherapy drugs, tumors utilize multiple pathways to resist immunotherapy, suggesting that combination approaches will be needed to achieve meaningful and durable responses. Success will likely require further elucidation of the mechanisms of resistance to existing immunotherapies, the development and testing of rational combination treatments to overcome this resistance, and the identification of predictive biomarkers to help guide appropriate use of these treatments. Although much work remains to be done, the hope is that immunotherapy can lead to breakthroughs that will revolutionize osteosarcoma therapy in the same way that adult cancer therapy has been transformed. 
